{"filing":{"accession_number":"0001104659-26-064863","cik":"0001455365","ticker":"CGTX","company_name":"COGNITION THERAPEUTICS INC","form":"8-K","filing_date":"2026-05-21","report_date":null,"primary_document":"tm2615260d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1455365/000110465926064863/tm2615260d1_8k.htm"},"events":[{"id":9312,"run_id":8168,"accession_number":"0001104659-26-064863","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"summary":"The disclosure announces completion of an FDA meeting regarding zervimesine for dementia with Lewy bodies patients with psychosis. This represents a material regulatory milestone for a clinical-stage biopharmaceutical company, but does not fit neatly into more specific categories (not an earnings release, M\u0026A activity, or litigation). FDA meeting outcomes can materially affect development timelines and investor expectations for drug candidates.","company_name":"COGNITION THERAPEUTICS INC","ticker":"CGTX","filing_date":"2026-05-21","form":"8-K","submitted_at":null,"items":[{"id":905,"accession_number":"0001104659-26-064863","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"The disclosure announces completion of an FDA meeting regarding zervimesine for dementia with Lewy bodies patients with psychosis. This represents a material regulatory milestone for a clinical-stage biopharmaceutical company, but does not fit neatly into more specific categories (not an earnings release, M\u0026A activity, or litigation). FDA meeting outcomes can materially affect development timelines and investor expectations for drug candidates.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-22T02:31:26.062284+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":905,"accession_number":"0001104659-26-064863","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"The disclosure announces completion of an FDA meeting regarding zervimesine for dementia with Lewy bodies patients with psychosis. This represents a material regulatory milestone for a clinical-stage biopharmaceutical company, but does not fit neatly into more specific categories (not an earnings release, M\u0026A activity, or litigation). FDA meeting outcomes can materially affect development timelines and investor expectations for drug candidates.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-22T02:31:26.062284+00:00","company_name":"COGNITION THERAPEUTICS INC","ticker":"CGTX","filing_date":"2026-05-21"}]}